A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
D015107:4-Butyrolactone / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism*; D005260:Female; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology*; D016627:Oxidopamine; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism; D013239:Stereotyped Behavior / Q000187:drug effects; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*
D006892:Hydroxydopamines; D009281:Naphthalenes; D010880:Piperidines; D011954:Receptors, Dopamine; D013764:Tetrahydronaphthalenes; D013134:Spiperone; C016893:2-(N,N-dimethylamino)-6,7-dihydroxytetralin; D016627:Oxidopamine; C026539:preclamol; D001058:Apomorphine; D015107:4-Butyrolactone